ReviewInflammation and regeneration2020
Regenerative therapy for spinal cord injury using iPSC technology.
Review in Inflammation and regeneration, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Efficacy of a cultured conditioned medium of exfoliated deciduous dental pulp stem cells in erectile dysfunction patients.Journal of cellular and molecular medicine · 2022Trial
- Human induced pluripotent stem cell-derived neural stem/progenitor cell therapy for spinal cord injury: preclinical advances and translational perspectives.Stem cells translational medicine · 2026Review
- Single-cell glycome and transcriptome profiling uncovers the glycan signature of each cell subpopulation of human iPSC-derived neurons.Stem cell reports · 2025Article
- Targeting ferroptosis in spinal cord injury through stem cell therapy: mechanisms and therapeutic prospects.Frontiers in neuroscience · 2025Review
- Epigenetic regulation and factors that influence the effect of iPSCs-derived neural stem/progenitor cells (NS/PCs) in the treatment of spinal cord injury.Clinical epigenetics · 2024Review
- Rapid and high-purity differentiation of human medium spiny neurons reveals LMNB1 hypofunction and subtype necessity in modeling Huntington's disease.Inflammation and regeneration · 2024Article
- Regenerative Potential of Injured Spinal Cord in the Light of Epigenetic Regulation and Modulation.Cells · 2023Review
- Immature human engineered heart tissues engraft in a guinea pig chronic injury model.Disease models & mechanisms · 2023Article
- Current Advancements in Spinal Cord Injury Research-Glial Scar Formation and Neural Regeneration.Cells · 2023Review
- A review of regenerative therapy for spinal cord injury using human iPS cells.North American Spine Society journal · 2023Article
- Hydrogel scaffolds in the treatment of spinal cord injury: a review.Frontiers in neuroscience · 2023Review
- Neural Stem Cells Overexpressing Arginine Decarboxylase Improve Functional Recovery from Spinal Cord Injury in a Mouse Model.International journal of molecular sciences · 2022Article
- A Narrative Review of Advances in Neural Precursor Cell Transplantation Therapies for Spinal Cord Injury.Neurospine · 2022Article
- Review
- Cancer cells as a new source of induced pluripotent stem cells.Stem cell research & therapy · 2022Review
- Non-human primate pluripotent stem cells for the preclinical testing of regenerative therapies.Neural regeneration research · 2022Review
- Identification of MAEL as a promoter for the drug resistance model of iPSCs derived from T-ALL.Cancer medicine · 2022Article
- Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination.Inflammation and regeneration · 2022Review
- Modulation by DREADD reveals the therapeutic effect of human iPSC-derived neuronal activity on functional recovery after spinal cord injury.Stem cell reports · 2022Article
- Cell transplantation to repair the injured spinal cord.International review of neurobiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating event that causes permanent neurologic impairments. Cell transplantation therapy using neural precursor cells (NPCs) is a promising intervention aiming to replace damaged neural tissue and restore certain functions. Because the protocol to produce human induced pluripotent stem cells (iPSCs) was first established, we have attempted to apply this technology for regenerative therapy in SCI. Our group reported beneficial effects of iPSC-derived NPC transplantation and addressed safety issues on tumorigenicity after grafting. These findings will soon be tested at the clinical trial stage, the protocol of which has already been approved by the Ministry of Health, Labour and Welfare in Japan. Current transplantation therapies treat patients at the subacute phase after injury, highlighting the need for effective treatments for chronic SCI. We recently demonstrated the modest efficacy of gamma secretase inhibitor treatment of iPSC-NPCs before transplantation at the chronic phase. However, more comprehensive strategies involving combinatory therapies are essential to enhance current spinal cord regeneration treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.